Niraparib (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Niraparib" in English language version.

refsWebsite

Global rank English rank

7nih.gov

4^th place

5fda.gov

447^th place

338^th place

3doi.org

2^nd place

2europa.eu

68^th place

117^th place

1hres.ca

low place

1medicines.org.uk

3,823^rd place

2,387^th place

1drugs.com

399^th place

333^rd place

1esmo.org

low place

1web.archive.org

1^st place

1fiercebiotech.com

low place

8,828^th place

doi.org

van Andel L, Zhang Z, Lu S, Kansra V, Agarwal S, Hughes L, et al. (December 2017). "14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer". Investigational New Drugs. 35 (6): 751–765. doi:10.1007/s10637-017-0451-2. PMC 5694528. PMID 28303528.
van Andel L, Rosing H, Zhang Z, Hughes L, Kansra V, Sanghvi M, et al. (January 2018). "14C-microtracer and therapeutic dose in cancer patients". Cancer Chemotherapy and Pharmacology. 81 (1): 39–46. doi:10.1007/s00280-017-3455-x. PMC 5754411. PMID 29043410.
Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. (November 2012). "Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors". Cancer Research. 72 (21): 5588–99. doi:10.1158/0008-5472.CAN-12-2753. PMC 3528345. PMID 23118055.

drugs.com

"Niraparib Monograph for Professionals". American Society of Health-System Pharmacists. 22 September 2020. Retrieved 17 January 2021.

esmo.org

"Niraparib Receives FDA Fast Track Designation for the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". The European Society for Medical Oncology (ESMO). 5 September 2016.

europa.eu

ema.europa.eu

"Zejula EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 17 January 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Zejula". European Medicines Agency. 17 September 2018. Archived from the original on 9 August 2018. Retrieved 29 May 2018.

fda.gov

"Niraparib (Zejula)". U.S. Food and Drug Administration (FDA). 30 March 2017. This article incorporates text from this source, which is in the public domain.
"FDA approves maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers". U.S. Food and Drug Administration (FDA) (Press release). 27 March 2017. Retrieved 17 January 2021. This article incorporates text from this source, which is in the public domain.
"Drug Trials Snapshots: Zejula". U.S. Food and Drug Administration (FDA). 27 March 2017. Retrieved 17 January 2021. This article incorporates text from this source, which is in the public domain.
"FDA approves niraparib for HRD-positive advanced ovarian cancer". U.S. Food and Drug Administration (FDA). 23 October 2019. Retrieved 17 January 2021. This article incorporates text from this source, which is in the public domain.
"FDA approves niraparib for first-line maintenance of advanced ovarian". U.S. Food and Drug Administration (FDA). 29 April 2020. Retrieved 17 January 2021. This article incorporates text from this source, which is in the public domain.

fiercebiotech.com

Adams B (29 June 2016). "Tesaro's PARP ovarian cancer drug hits PhIII goal; prepares to file". Fierce Biotech.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision (SBD) for Zejula". Health Canada. 23 October 2014. Retrieved 29 May 2022.

medicines.org.uk

"Zejula 100 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). Retrieved 17 January 2021.

nih.gov

ncbi.nlm.nih.gov

van Andel L, Zhang Z, Lu S, Kansra V, Agarwal S, Hughes L, et al. (December 2017). "14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer". Investigational New Drugs. 35 (6): 751–765. doi:10.1007/s10637-017-0451-2. PMC 5694528. PMID 28303528.
van Andel L, Rosing H, Zhang Z, Hughes L, Kansra V, Sanghvi M, et al. (January 2018). "14C-microtracer and therapeutic dose in cancer patients". Cancer Chemotherapy and Pharmacology. 81 (1): 39–46. doi:10.1007/s00280-017-3455-x. PMC 5754411. PMID 29043410.
Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. (November 2012). "Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors". Cancer Research. 72 (21): 5588–99. doi:10.1158/0008-5472.CAN-12-2753. PMC 3528345. PMID 23118055.

pubmed.ncbi.nlm.nih.gov

van Andel L, Zhang Z, Lu S, Kansra V, Agarwal S, Hughes L, et al. (December 2017). "14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer". Investigational New Drugs. 35 (6): 751–765. doi:10.1007/s10637-017-0451-2. PMC 5694528. PMID 28303528.
van Andel L, Rosing H, Zhang Z, Hughes L, Kansra V, Sanghvi M, et al. (January 2018). "14C-microtracer and therapeutic dose in cancer patients". Cancer Chemotherapy and Pharmacology. 81 (1): 39–46. doi:10.1007/s00280-017-3455-x. PMC 5754411. PMID 29043410.
Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. (November 2012). "Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors". Cancer Research. 72 (21): 5588–99. doi:10.1158/0008-5472.CAN-12-2753. PMC 3528345. PMID 23118055.

dailymed.nlm.nih.gov

"Zejula- niraparib capsule". DailyMed. Retrieved 17 January 2021.

web.archive.org

"Zejula". European Medicines Agency. 17 September 2018. Archived from the original on 9 August 2018. Retrieved 29 May 2018.